Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.43 |
| ▸ | SIRT2 | Q8IXJ6 | 6/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TAS2R14 | Q9NYV8 | 6/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.40 |
| ▸ | YAP1 | P46937 | 1/20 | 0.40 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.40 |
| ▸ | TEAD2 | Q15562 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22571369 | 0.80 | SIRT2 (0.62) | RXFP1MAPK8SIRT2PTGS1TAS2R14 | |
| SCHEMBL21764748 | 0.80 | RXFP1 (0.47) | RXFP1MAPK8SIRT2PTGS1KDM4E | |
| SCHEMBL20553269 | 0.77 | RXFP1 (0.58) | RXFP1MAPK8SIRT2PTGS1MEN1 | |
| SCHEMBL22571440 | 0.75 | ABCG2 (0.41) | MAPK8KDM4EMEN1ALDH1A1GAA | |
| SCHEMBL4245559 | 0.75 | MAPK8 (0.67) | RXFP1MAPK8PTGS1MEN1ALDH1A1 | |
| SCHEMBL1921457 | 0.75 | ALDH1A1 (0.55) | KDM4EMEN1ALDH1A1GAAMAPT | |
| SCHEMBL12253491 | 0.74 | AKR1C3 (0.48) | RXFP1MAPK8SIRT2PTGS1KDM4E | |
| SCHEMBL25279533 | 0.74 | AKR1C3 (0.60) | RXFP1MAPK8SIRT2PTGS1MEN1 | |
| SCHEMBL22556306 | 0.73 | RXFP1 (0.53) | RXFP1MAPK8SIRT2PTGS1GAA | |
| SCHEMBL22571345 | 0.72 | SIRT2 (0.42) | RXFP1MAPK8SIRT2PTGS1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186554-B2 | Non-fused tricyclic compounds | VIVACE THERAPEUTICS, INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20200062721-A1 | NON-FUSED TRICYCLIC COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062721-A1 | NON-FUSED TRICYCLIC COMPOUNDS | YAP1, MYC, TEAD2 | RXFP1 3462/4885MAPK8 1114/4885SIRT2 1545/4885 |
| US-11186554-B2 | Non-fused tricyclic compounds | YAP1, MYC, TEAD2 | RXFP1 3462/4885MAPK8 1114/4885SIRT2 1545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.